XML 44 R20.htm IDEA: XBRL DOCUMENT
v3.25.2

PIPE Financing - Private Placement and Warrants | 12 Months Ended
--- | ---
Mar. 31, 2025
PIPE Financing Private Placement and Warrants [Abstract] |
PIPE Financing - Private Placement and Warrants | 14. PIPE Financing - Private Placement and Warrants Private placement On December 24, 2024, the Company completed a private placement with HC Wainwright & Co., LLC (“HCW”), raising gross proceeds of $2,000,000 through the issuance of:
| ● | 47,679 common shares,
| ● | 77,792 pre-funded warrants (each exercisable into one common share at a nominal exercise price of $0.000797), and
| ● | 250,942 common share p urchase warrants, comprising:
| o | 125,471 warrants with an exercise price of $15.94 and a 5-year term (expiring December 24, 2029), and
| o | 125,471 warrants with an exercise price of $15.94 and a 2-year term (expiring December 24, 2026).
The proceeds were allocated between the common shares and the warrants based on their relative fair values on the date of issuance. The fair value allocation was as follows:
Fair value allocation |  |  |
Component |  | Allocated Amount |
Common shares |  | $ | 313,628 |
Pre-funded warrants |  | $ | 511,690 |
Warrants |  | $ | 1,174,682 |
Total gross proceeds |  | $ | 2,000,000 |
Fair value allocation assumptions The common shares were estimated using the share price on date of issuance - $19.37. The pre-funded warrants and the warrants were estimated using a Black Scholes valuation model using the following estimates:
|  | Pre-funded warrants |  |  | Warrants with 5 year expiry |  |  | Warrant with 2 year expiry |
Share price |  | $ | 19.37 |  |  | $ | 19.37 |  |  | $ | 19.37 |
Expected dividend yield |  |  | Nil |  |  |  | Nil |  |  |  | Nil |
Exercise price |  | $ | 0.00 |  |  | $ | 15.94 |  |  | $ | 15.94 |
Risk-free interest rate |  |  | 3.63 | % |  |  | 3.63 | % |  |  | 3.63 | %
Expected life |  |  | - |  |  |  | 5.00 |  |  |  | 2.00 |
Expected volatility |  |  | 100 | % |  |  | 100 | % |  |  | 100 | %
Expiry date |  |  | - |  |  |  | December 24, 2029 |  |  |  | December 24, 2026 |
Share Issuance Costs The Company incurred $257,949 in cash settled share issuance costs, which were allocated proportionately to the equity instruments issued. The portion related to the common shares, $40,449, was deducted from share capital, and the portion related to the warrants, $217,500, was deducted from the warrant reserve. The Company also incurred $137,778 in warrant settled issuance costs, 9,409 warrants, which was allocated to warrant reserve. Pre-funded Warrant Exercise During the year ended March 31, 2025, all 77,792 pre-funded warrants were exercised. An amount of $511,690, representing the fair value originally allocated to the pre-funded warrants, was reclassified from warrant reserve to share capital upon exercise. An amount of $66,003 of share issuance costs was reallocated to share capital upon exercise. All instruments issued in the private placement were classified as equity instruments, as they did not contain any contractual obligations to deliver cash or other financial assets and met the fixed-for-fixed condition.

X
- Definition The entire disclosure for private placement and warrants. + References No definition available. + Details
Name: | pbm_DisclosureOfPrivatePlacementAndWarrantsExplanatory
Namespace Prefix: | pbm_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition N/A + References No definition available. + Details
Name: | pbm_PrivatePlacementAndWarrantsAbstract
Namespace Prefix: | pbm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration